TSLP inhibitors and receptor antagonists present significant market opportunities for treating various inflammatory diseases due to their ability to modulate key inflammatory pathways. Expanding ...

CD73 inhibitors present significant opportunities in cancer immunotherapy by reversing immunosuppression in tumors and enhancing immune response. Novel antibodies, RNA, and small molecules are in ...

The market opportunities for TL1A Inhibitors and DR3 Antagonists focus on their potential to address inflammatory bowel disease, evidenced by heightened interest from major pharmaceutical companies.

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract ...

LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the ...

First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline - - Announced FDA Approval of VEPPANU (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced ...

Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-1181 ...

Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic ...

Trump’s Iran war and the collapse of arms control may trigger a global nuclear race. How US policy reshaped deterrence and ...